Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Sinda Bigenzahn"'
Autor:
Sinda Bigenzahn, Ines Pree, Christoph Klaus, Nina Pilat, Benedikt Mahr, Elisabeth Schwaiger, Patrick Nierlich, Friedrich Wrba, Thomas Wekerle
Publikováno v:
Journal of Immunology Research, Vol 2016 (2016)
Mixed chimerism and tolerance can be successfully induced in rodents through allogeneic bone marrow transplantation (BMT) with costimulation blockade (CB), but varying success rates have been reported with distinct models and protocols. We therefore
Externí odkaz:
https://doaj.org/article/3ec33d2db81c48fca68600e03e2789f0
Autor:
Alexander Kainz, Thomas Wekerle, Dietmar Fuchs, Sinda Bigenzahn, Ferdinand Muehlbacher, B Juergens, A Koenigsrainer, Gerald Brandacher, Johann Pratschke, T Becker, Benedikt Mahr
Publikováno v:
Clinical and Experimental Immunology. 192:233-241
Summary Belatacept is a second-generation cytotoxic T lymphocyte antigen (CTLA)-4 immunoglobulin (Ig) fusion protein approved for immunosuppression in renal transplant recipients. It was designed intentionally to interrupt co-stimulation via CD28 by
Autor:
Yannick D Muller, Gang Mai, Philippe Morel, Véronique Serre-Beinier, Carmen Gonelle-Gispert, Gisella Puga Yung, Driss Ehirchiou, Jean-Christophe Wyss, Sinda Bigenzahn, Magali Irla, Christoph Heusser, Déla Golshayan, Jörg D Seebach, Thomas Wekerle, Leo H Bühler
Publikováno v:
PLoS ONE, Vol 5, Iss 4, p e10352 (2010)
BACKGROUND: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve survival of rat-to-mouse islet xenograft. The present study investigated the effect of combined RAPA/MR1 treatment on rat-to-mouse islet xenograft surv
Externí odkaz:
https://doaj.org/article/7b2f6edb0d8748e6bd2e5084c660d39a
Autor:
Michael Gnant, Peter Blaha, Peter Dubsky, Ruth Exner, Florian Fitzal, Emanuel Sporn, Peter Panhofer, Andrea Dal Borgo, Sinda Bigenzahn, Guenther Steger, Raimund Jakesz
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 1 (2009)
Recent advances in the treatment of early breast cancer have improved clinical outcomes and prolonged survival, especially in women with endocrine-responsive disease. However, cancer therapies including cytotoxic chemotherapy, ovarian suppression, an
Externí odkaz:
https://doaj.org/article/b7180a7594b9467988b6dab4282d8b84
Autor:
Ines Pree, Christoph Klaus, Ferdinand Muehlbacher, Nina Pilat, Thomas Wekerle, Zvonimir Koporc, Masaru Taniguchi, Ulrike Baranyi, Patrick-Nikolaus Nierlich, Sinda Bigenzahn
Publikováno v:
Transplant International. 23:1179-1189
Distinct lymphocyte populations have been identified that either promote or impede the establishment of chimerism and tolerance through allogeneic bone marrow transplantation (BMT). Natural killer T (NKT) cells have pleiotropic regulatory properties
Autor:
E. Sporn, Sinda Bigenzahn, Ursula Pluschnig, Peter Dubsky, Andrea Dal Borgo, Guenther G. Steger, Sebastian F. Schoppmann, Raimund Jakesz, Florian Fitzal, Peter Blaha, Michael Gnant, Thomas Bachleitner-Hofmann, Ruth Exner, O. Riedl, Peter Panhofer
Publikováno v:
Breast Care. 4:155-161
Endocrine therapy has become a key part in the adjuvant treatment of hormone responsive breast cancer. The positive effect on relapse risk reduction is well defined, but therapy is not free from bothersome side effects for which estrogen deprivation
Autor:
Peter Blaha, Thomas Wekerle, Edgar Selzer, Friedrich Wrba, Ines Pree, Kathrin Wagner, Sinda Bigenzahn, Christoph Heusser, Zvonimir Koporc, Ferdinand Muehlbacher, Helga Bergmeister
Publikováno v:
American Journal of Transplantation. 5:1237-1247
Peripheral and central clonal deletion are important tolerance mechanisms in models using bone marrow transplantation (BMT) with costimulation blockade (CB). However, since tolerance can be found before peripheral deletion is complete and since elimi
Publikováno v:
Scopus-Elsevier
Autor:
Peter Panhofer, Florian Fitzal, Peter Dubsky, Raimund Jakesz, Sinda Bigenzahn, Andrea Dal Borgo, Ruth Exner, E. Sporn, Guenther G. Steger, Peter Blaha, Michael Gnant
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 1 (2009)
Recent advances in the treatment of early breast cancer have improved clinical outcomes and prolonged survival, especially in women with endocrine-responsive disease. However, cancer therapies including cytotoxic chemotherapy, ovarian suppression, an
Autor:
Gisella Puga Yung, Sinda Bigenzahn, Jorg Dieter Seebach, Yannick D. Muller, Christoph Heusser, Carmen Gonelle-Gispert, Jean-Christophe Wyss, Véronique Serre-Beinier, Philippe Morel, Thomas Wekerle, Gang Mai, Magali Irla, Dela Golshayan, Driss Ehirchiou, Leo Buhler
Publikováno v:
PloS one, vol. 5, no. 4, pp. e10352
PLOS ONE, Vol. 5, No 4 (2010) P. e10352
PLoS ONE
PLoS ONE, Vol 5, Iss 4, p e10352 (2010)
PLOS ONE, Vol. 5, No 4 (2010) P. e10352
PLoS ONE
PLoS ONE, Vol 5, Iss 4, p e10352 (2010)
BACKGROUND: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve survival of rat-to-mouse islet xenograft. The present study investigated the effect of combined RAPA/MR1 treatment on rat-to-mouse islet xenograft surv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f0a82a833d99502c65872b3aa8b8eda
https://serval.unil.ch/notice/serval:BIB_54F43515C73B
https://serval.unil.ch/notice/serval:BIB_54F43515C73B